-
Date: 28 November 2011
On November 23, The George Institute for Global Health, China, the Chinese Diabetes Society, and Sanofi jointly launched the ORBIT study (Observational Registry for Basal Insulin Treatment) in Beijing.
Diabetes is a major health and economic burden all around the world. China’s growing population is increasingly affected by diabetes, making the condition a pivotal healthcare issue. Currently, many type 2 diabetes patients in China start using insulin much later than is recommended by Chinese diabetes guidelines, and often the dosage is suboptimal and patient self-monitoring is limited.
Further complicating the quality of patient care is a lack of support in the health system for diabetes management. How basal insulin therapy can help improve the situation in the healthcare system and remain cost-effective is unclear.
ORBIT is the largest study on basal insulin ever conducted in China and involves 20,000 type 2 diabetes patients nationwide. The objective of the study is to evaluate basal insulin use in the real world and whether it can be an effective tool in the management of diabetes in China.
“The ORBIT study will not only examine the effectiveness and safety of basal insulin treatment, but also explore the factors associated with effectiveness and safety. It is expected that the ORBIT study will be a milestone in basal insulin treatment in clinical practice for type 2 diabetes and shed light on diabetes control and management in China,” said Professor JiLinong, President of the CDS and Principle Investigator of the ORBIT study.
“High-quality execution of the study is critical in delivering the most scientific and rigorous outcome. Thus, The George Institute has established a dedicated team for the research design, project management, data and statistical analysis for the study. The institute is honored to cooperate with CDS and Sanofi to help type 2 diabetes patients in China reach the optimal outcome of disease management,” added Professor Wu Yangfeng, Executive Director of The George Institute for Global Health, China.
Establishing a strong support system at the hospital level and ensuring that physicians, nurses and patients have the best information on diabetes management is a key question that ORBIT is investigating. Working with patients, physicians and hospitals over 6 months, some of the preliminary results are expected to be delivered by the end of 2013.
The study was initiated by Chinese Diabetes Society (CDS) and will be conducted by The George Institute for Global Health, China with the financial support of Sanofi.
If you would like to find out more information about the ORBIT study, please visit our website at www.georgeinstitute.org.cn or contact Ye Erken (Ken) at yerken@georgeinstitute.org.cn or +86 10 8280 0577-602.
